Why trust will shape the next phase of health data AI

Tern plc

Artificial intelligence is opening a significant opportunity in healthcare, but the real issue is not just technical capability. It is whether companies can turn sensitive health data into useful intelligence without creating regulatory, reputational or adoption risk.

Patient conversations, clinician notes, forums, support groups and wider lived experience often contain early signals on treatment effectiveness, side effects, adherence problems, unmet need and changing disease patterns. Traditional analytics has struggled to use this material because it is messy, context-dependent and difficult to standardise. AI is beginning to change that by turning fragmented discussion into structured insight that can be used by life sciences companies and healthcare decision-makers.

Better interpretation of real-world patient and clinician dialogue can help businesses identify safety signals earlier, understand treatment barriers, refine market strategy and improve how they prioritise development. In practical terms, that means stronger positioning, earlier signal detection and better decision-making across the product lifecycle. But that opportunity only holds if the intelligence is trusted.

In health data, weak governance is not a side issue. It can directly affect whether a company’s product is adopted, whether its data can be used with confidence and whether its operating model can scale under growing scrutiny. If an AI system introduces bias, misreads context or fails to protect privacy, the damage goes beyond compliance. It can reduce credibility with regulators, clinicians, patients and commercial partners.

Healthcare users do not need every detail of a proprietary model, but they do need to understand how data is collected, how it is processed, how conclusions are reached and how systems are validated. Clear data provenance, explainable methods, auditable model development and documented bias monitoring all help move AI from a black box to something stakeholders can rely on.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search